What is TECH's market cap?

$11.42B, based on the Nov 4 close of $72.73.

What is TECH's P/E ratio?

62.8× trailing-twelve-month earnings of $181.86M.

Does Bio-Techne pay a dividend?

Yes. The latest regular dividend was $0.08 per share (ex-date Aug 24), an annualised yield of 0.44%.

How much of TECH is sold short?

7.6M shares, 4.8% of float, as of Oct 15, 2026.

What sector is TECH in?

Healthcare, in the Biotechnology industry.

NASDAQ · TECHHealthcareBiotechnology

Bio-Techne Corp. (TECH)

$72.73+0.10%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$72.73▲ 19.03% in range

Nov 4, 2025Low $43.30 · High $72.73Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Bio-Techne closed at $72.73 on Nov 4, up 0.10% — matching its 52-week closing high. Volume of 4.2M shares was 1.49× its 20-day average (above normal).

Split-adjusted performance: +0.4% over one month, +53.4% over six months, +18.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $321.19M, up 1.3% from a year earlier, with a net margin of 17.0%.

Short interest was 7.6M shares at the Oct 15 settlement, up 2.3% from the prior report (4.8% of float, 2.9 days to cover).

Market cap$11.42B157.1M shares

Revenue · quarter$321.2M+1.3% YoY

Diluted EPS$0.35—

P/E · TTM62.8×P/S 9.4×

Net margin17.0%Gross 65.8%

Dividend yield0.44%$0.08 last paid

52-week range43.30 – 72.730.0% from high

Volume4.2M1.49× 20-day avg

Volatility · 60d2.2%Annualised

Short % of float4.8%2.9 days to cover

Net cash$64.7MCash $264.7M

Next earnings—Not scheduled

Split-adjusted performance

1W +0.1%1M +0.4%3M +1.2%6M +53.4%YTD +23.7%1Y +18.7%3Y +28.4%5Y −42.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum91

Revenue growth38

Net margin78

Value (low P/E)15

Size94

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short7.6M+2.3% vs prior

Days to cover2.9Settled Oct 15

% of float4.8%

Short vol. 10d39.9%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
TECHBio-Techne	$72.73	+0.10%	+53.4%	+1.3%	17.0%	62.8	$11.42B
RGENRepligen	$178.20	−0.04%	+41.7%	+10.9%	−18.4%	—	$11.31B	Compare
KYMRKymera Therapeutics	$136.25	+7.21%	+58.0%	−100.0%	—	—	$11.63B	Compare
PCVXVaxcyte	$65.68	+8.01%	+15.0%	—	—	—	$10.34B	Compare
IBRXImmunityBio	$8.93	+7.72%	+6.6%	+93.9%	−449.6%	—	$9.46B	Compare
TWSTTwist Bioscience	$142.58	+1.63%	+139.5%	+23.2%	−29.6%	—	$9.45B	Compare
KRYSKrystal Biotech	$310.84	+1.90%	+7.6%	+30.2%	49.5%	40.9	$9.20B	Compare
HALOHalozyme Therapeutics	$130.34	+1.34%	+96.4%	+47.7%	47.8%	35.8	$14.79B	Compare
NBIXNeurocrine Biosciences	$166.05	+0.73%	+12.9%	+41.2%	18.4%	24.0	$16.88B	Compare

News about Bio-Techne

All news →

Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?Zacks Investment Research · 2d ago▲ Positive INCY or TECH: Which Is the Better Value Stock Right Now?Zacks Investment Research · Sep 30, 2026▼ Negative Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?Zacks Investment Research · Sep 11, 2026Neutral $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger – AUUD, TECH, CZR and CBANGlobeNewswire Inc. · Sep 9, 2026Neutral Halper Sadeh LLC is Investigating Whether ACA, TECH, IRDM, LCII are Obtaining Fair Deals for their ShareholdersGlobeNewswire Inc. · Jul 6, 2026▼ Negative

Quick answers

What does Bio-Techne do?: Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%).
What is TECH's market cap?: $11.42B, based on the Nov 4 close of $72.73.
What is TECH's P/E ratio?: 62.8× trailing-twelve-month earnings of $181.86M.
Does Bio-Techne pay a dividend?: Yes. The latest regular dividend was $0.08 per share (ex-date Aug 24), an annualised yield of 0.44%.
How much of TECH is sold short?: 7.6M shares, 4.8% of float, as of Oct 15, 2026.
What sector is TECH in?: Healthcare, in the Biotechnology industry.

About Bio-Techne

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

HQ: Minneapolis, MN3,000 employeesListed May 8, 1989bio-techne.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology